Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nicorandil, a potent adenosine triphosphate–sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury  Motohiro Yamashita, MD,

Similar presentations


Presentation on theme: "Nicorandil, a potent adenosine triphosphate–sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury  Motohiro Yamashita, MD,"— Presentation transcript:

1 Nicorandil, a potent adenosine triphosphate–sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury  Motohiro Yamashita, MD, Ralph A. Schmid, MD, Shozo Fujino, MD, Joel D. Cooper, MD, FRCS(C), G.Alexander Patterson, MD, FRCS(C)  The Journal of Thoracic and Cardiovascular Surgery  Volume 112, Issue 5, Pages (November 1996) DOI: /S (96) Copyright © 1996 Mosby, Inc. Terms and Conditions

2 Fig. 1 Arterial oxygen tension (Pao 2 ) and arterial carbon dioxide tension (Paco 2 ) for groups I, II, and III through the 6-hour assessment. There was significant difference in Pao2 (p < 0.01) between groups I and II, but there were no significant differences in Paco2 among the three groups. NS, Not significant. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

3 Fig. 1 Arterial oxygen tension (Pao 2 ) and arterial carbon dioxide tension (Paco 2 ) for groups I, II, and III through the 6-hour assessment. There was significant difference in Pao2 (p < 0.01) between groups I and II, but there were no significant differences in Paco2 among the three groups. NS, Not significant. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

4 Fig. 2 Hemodynamic data during the 6-hour assessment. There were no statistical differences in mean aortic pressure (AoP) and mean pulmonary pressure among the three groups over time. Cardiac output (C.O.) in group II was higher than in groups I and III (p < 0.05) over time. Pulmonary vascular resistance (PVR) in group III was higher than in group II (p < 0.05) over time. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

5 Fig. 2 Hemodynamic data during the 6-hour assessment. There were no statistical differences in mean aortic pressure (AoP) and mean pulmonary pressure among the three groups over time. Cardiac output (C.O.) in group II was higher than in groups I and III (p < 0.05) over time. Pulmonary vascular resistance (PVR) in group III was higher than in group II (p < 0.05) over time. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

6 Fig. 2 Hemodynamic data during the 6-hour assessment. There were no statistical differences in mean aortic pressure (AoP) and mean pulmonary pressure among the three groups over time. Cardiac output (C.O.) in group II was higher than in groups I and III (p < 0.05) over time. Pulmonary vascular resistance (PVR) in group III was higher than in group II (p < 0.05) over time. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

7 Fig. 3 Tissue MPO activity after the 6-hour assessment. MPO activity in group II was significantly lower than in groups I and III (p < 0.05). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

8 Fig. 4 Results of BALF protein level after the assessment period. BALF protein concentration from allograft in group II was significantly lower than in group I (p < 0.05). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

9 Table III Mechanism of KATP-channel opener
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions


Download ppt "Nicorandil, a potent adenosine triphosphate–sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury  Motohiro Yamashita, MD,"

Similar presentations


Ads by Google